281 related articles for article (PubMed ID: 23918607)
1. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
2. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
4. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
7. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
9. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
Barwick BG; Abramovitz M; Kodani M; Moreno CS; Nam R; Tang W; Bouzyk M; Seth A; Leyland-Jones B
Br J Cancer; 2010 Feb; 102(3):570-6. PubMed ID: 20068566
[TBL] [Abstract][Full Text] [Related]
11. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
14. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
[TBL] [Abstract][Full Text] [Related]
15. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
16. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
18. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]